Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666835 | 1.00 | SCN3A (0.52) | SCN3AMEN1KMT2APRCPSMYD3 | |
| SCHEMBL29474880 | 1.00 | SCN3A (0.52) | SCN3AMEN1KMT2APRCPSMYD3 | |
| SCHEMBL32677003 | 1.00 | SCN3A (0.52) | SCN3AMEN1KMT2APRCPSMYD3 | |
| SCHEMBL32677100 | 1.00 | SCN3A (0.52) | SCN3AMEN1KMT2APRCPSMYD3 | |
| Hydrochloric Acid SCHEMBL30225627 | 0.98 | MEN1 (0.51) | SCN3AMEN1KMT2APRCPSMYD3 | |
| Hydrochloric Acid SCHEMBL29897791 | 0.98 | MEN1 (0.51) | SCN3AMEN1KMT2APRCPSMYD3 | |
| Hydrochloric Acid SCHEMBL27787267 | 0.98 | MEN1 (0.51) | SCN3AMEN1KMT2APRCPSMYD3 | |
| Hydrochloric Acid SCHEMBL4787147 | 0.98 | MEN1 (0.51) | SCN3AMEN1KMT2APRCPSMYD3 | |
| SCHEMBL288272 | 0.83 | GAA (0.58) | MEN1KMT2APRCPPNMTOPRM1 | |
| SCHEMBL288260 | 0.83 | GAA (0.58) | MEN1KMT2APRCPPNMTOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512832-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | Research Triangle Institute, International (US) | 2019-07-24 | — | — | EP | claimed |
| CN-109790125-A | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | 研究三角协会 | 2019-05-21 | — | — | CN | claimed |
| WO-2018053222-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RESEARCH TRAINGLE INSTITUTE (US) | 2018-03-22 | — | — | WO | claimed |
| CN-104540806-B | Azaheterocycles as BIR2 and/or BIR3 inhibitors | 霍夫曼-拉罗奇有限公司 | 2017-05-03 | — | — | CN | claimed |
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-04-21 | — | — | US | claimed |
| EP-2195034-A2 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | Amylin Pharmaceuticals, Inc. (US) | 2010-06-16 | — | — | EP | claimed |
| EP-2125799-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2009042922-A2 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| WO-2008104524-A1 | THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-04 | — | — | WO | claimed |
| WO-2006055951-A2 | TETRAHYDROISOQUINOLINES AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| WO-1998047877-A1 | 2-BENZOYL-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HEPATIC PRODUCTION OF APOB-100 | GLAXO GROUP LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| US-12503455-B2 | Nucleic acid-binding photoprobes and uses thereof | ARRAKIS THERAPEUTICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11807623-B2 | Nucleic acid-binding photoprobes and uses thereof | ARRAKIS THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-5994545-A | TETRAHYDROISOQUINOLINE-3(S)-CARBOXYLIC ACID N-CARBOXY ANHYDRIDE; INTERMEDIATES OF SAQUINAVIR (EP 432694). | AJINOMOTO CO., INC. (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5948886-A | ELASTASE INHIBITORS OR PRODRUGS; FOR TREATMENT OF EMPHYSEMA, CYSTIC FIBROSIS, ADULT RESPIRATORY DISTRESS SYNDROME, GOUT, DISSEMINATED INTRAVASCULAR COAGULATION, RHEUMATOID ARTHRITIS, CHRONIC BRONCHITIS, INFLAMMATORY BOWEL DISEASE, SEPTICEMIA | HOECHST MARION ROUSSEL, INC. (US) | 1999-09-07 | — | — | US | disclosed |
| EP-0751128-B1 | Process for producing optically active amides | AJINOMOTO KK (JP) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998047877-A1 | 2-BENZOYL-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HEPATIC PRODUCTION OF APOB-100 | GLAXO GROUP LIMITED (GB) | 1998-10-29 | — | — | WO | disclosed |
| EP-0751128-A1 | Process for producing optically active amides | Ajinomoto Co., Ltd. (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | SCN3A 929/4885MEN1 4872/4885KMT2A 3661/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | SCN3A 149/4885MEN1 4097/4885KMT2A 1593/4885 |
| US-12503455-B2 | Nucleic acid-binding photoprobes and uses thereof | NSUN3, NSUN2, TARBP1 | SCN3A 4664/4885MEN1 4474/4885KMT2A 2159/4885 |
| US-20160108406-A1 | METHOD OF REGULATING CFTR EXPRESSION AND PROCESSING | CFTR, NEDD8, SCNN1B | SCN3A 474/4885MEN1 2750/4885KMT2A 2228/4885 |
| US-11807623-B2 | Nucleic acid-binding photoprobes and uses thereof | NSUN3, NSUN2, TARBP1 | SCN3A 4664/4885MEN1 4474/4885KMT2A 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.